HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

(2010) P. L. Zinzani et al.   CLINICAL CANCER RESEARCH

A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters

(2010) A. K. Nowak et al.   CLINICAL CANCER RESEARCH

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab

(2010) Tapan K. Nayak et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

PET imaging of tumor angiogenesis in mice with VEGF-A-targeted 86Y-CHX-A″-DTPA-bevacizumab

(2010) Tapan K. Nayak et al.   INTERNATIONAL JOURNAL OF CANCER

Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma

(2010) T. K. Nayak et al.   JOURNAL OF NUCLEAR MEDICINE

Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma

(2010) Rabab Gaafar et al.   LUNG CANCER

Malignant Pleural Mesothelioma

(2009) Anne S. Tsao et al.   JOURNAL OF CLINICAL ONCOLOGY

Asbestos-induced lung diseases: an update

(2009) David W. Kamp   Translational Research

Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

(2008) W Wang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis

(2008) Haining Yang et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Epidermal growth factor receptor gene mutation, amplification and protein expression in malignant pleural mesothelioma

(2008) K. Okuda et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY